Role of Cardiovascular Biomarkers in the Risk Stratification, Monitoring, and Management of Patients with Cancer

Christopher W. Hoeger, Salim S. Hayek

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

Cardiovascular effects of cancer therapies are of concern. Prediction, diagnosis, and management of cardiotoxicity is a challenge. Cardiovascular biomarkers are being studied in relationship to cancer therapy, showing promise in detection and prevention of cardiotoxicity. We summarize the use of biomarkers in cardio-oncology and presents recommendations for their use. Troponins and natriuretic peptides are the most commonly used biomarkers. High-quality evidence supporting their use is lacking. Biomarkers can be incorporated into a detection strategy for cardiotoxicity. Large, well-powered studies are needed to delineate care strategies using biomarkers in the prediction and management of the cardiovascular effects of cancer therapy.

Original languageEnglish (US)
Pages (from-to)505-523
Number of pages19
JournalCardiology Clinics
Volume37
Issue number4
DOIs
StatePublished - Nov 2019
Externally publishedYes

Keywords

  • Anthracycline
  • Biomarkers
  • Brain natriuretic peptide
  • Cancer
  • Cardiotoxicity
  • Chemotherapy
  • Trastuzumab
  • Troponin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Role of Cardiovascular Biomarkers in the Risk Stratification, Monitoring, and Management of Patients with Cancer'. Together they form a unique fingerprint.

Cite this